Your browser doesn't support javascript.
loading
Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges.
Han, Jinming; Chitu, Violeta; Stanley, E Richard; Wszolek, Zbigniew K; Karrenbauer, Virginija Danylaité; Harris, Robert A.
Afiliación
  • Han J; Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Chitu V; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
  • Stanley ER; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
  • Wszolek ZK; Department of Neurology, Mayo Clinic, Jacksonville, USA.
  • Karrenbauer VD; Department of Clinical Neuroscience, Center for Molecular Medicine L8:04, Karolinska Institutet, Karolinska University Hospital, 171 76, Stockholm, Sweden. virginija.karrenbauer@ki.se.
  • Harris RA; Department of Neurology, Karolinska University Hospital, Stockholm, Sweden. virginija.karrenbauer@ki.se.
Cell Mol Life Sci ; 79(4): 219, 2022 Apr 02.
Article en En | MEDLINE | ID: mdl-35366105
Microglia are specialized dynamic immune cells in the central nervous system (CNS) that plays a crucial role in brain homeostasis and in disease states. Persistent neuroinflammation is considered a hallmark of many neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and primary progressive multiple sclerosis (MS). Colony stimulating factor 1-receptor (CSF-1R) is predominantly expressed on microglia and its expression is significantly increased in neurodegenerative diseases. Cumulative findings have indicated that CSF-1R inhibitors can have beneficial effects in preclinical neurodegenerative disease models. Research using CSF-1R inhibitors has now been extended into non-human primates and humans. This review article summarizes the most recent advances using CSF-1R inhibitors in different neurodegenerative conditions including AD, PD, HD, ALS and MS. Potential challenges for translating these findings into clinical practice are presented.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Enfermedades Neurodegenerativas / Enfermedad de Alzheimer Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Cell Mol Life Sci Asunto de la revista: BIOLOGIA MOLECULAR Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Enfermedades Neurodegenerativas / Enfermedad de Alzheimer Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Cell Mol Life Sci Asunto de la revista: BIOLOGIA MOLECULAR Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza